Hormone receptor-positive/HER2 negative breast cancer
Clinical trials for Hormone receptor-positive/HER2 negative breast cancer explained in plain language.
Never miss a new study
Get alerted when new Hormone receptor-positive/HER2 negative breast cancer trials appear
Sign up with your email to follow new studies for Hormone receptor-positive/HER2 negative breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill combo shows promise in shrinking breast tumors before surgery
Disease control CompletedThis phase 2 trial tested whether adding the experimental drug PF-07220060 to the standard hormone therapy letrozole works better than letrozole alone in postmenopausal women with a common type of breast cancer (HR+/HER2-). The 121 participants took the pills for 14 days before t…
Matched conditions: HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New combo shows promise against Hard-to-Treat breast cancer
Disease control CompletedThis study tested whether adding the experimental drug samuraciclib to standard hormone therapy (fulvestrant) works better than fulvestrant alone for people with advanced HR+/HER2- breast cancer. The trial enrolled 60 adults whose cancer had worsened despite prior treatment. Rese…
Matched conditions: HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER
Phase 2 • Sponsor: Carrick Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New immunotherapy cocktails aim to tackle Hard-to-Treat breast cancer
Disease control CompletedThis study tested several immunotherapy-based drug combinations in 144 people with advanced hormone receptor-positive, HER2-negative breast cancer that had worsened after initial treatment. Participants received atezolizumab (Tecentriq) along with other drugs like bevacizumab or …
Matched conditions: HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER
Phase 1/2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC